Literature DB >> 30510607

MRI findings of hypomyelination in adenylosuccinate lyase deficiency.

Samar Kayfan1, Rana M Yazdani1, Samantha Castillo1, Kevin Wong2, Jeffrey H Miller2, Cory M Pfeifer1.   

Abstract

Adenylosuccinate lyase deficiency is a rare genetic disorder with few reported cases in the United States. Magnetic resonance imaging findings in the brain include hypomyelination and low generalized parenchymal volume. Presented here is a case in a 3-month-old male who presented with hypotonia and seizures and was subsequently diagnosed with adenylosuccinate lyase deficiency. Given the rarity of this diagnosis, findings demonstrated in this case may prompt ordering physicians to broaden their approach to genetic testing in the setting of hypomyelination. Comparison is also made to more common hypomyelinating leukodystrophies.

Entities:  

Keywords:  Adenylosuccinate lyase deficiency; Hypomyelination

Year:  2018        PMID: 30510607      PMCID: PMC6260459          DOI: 10.1016/j.radcr.2018.11.001

Source DB:  PubMed          Journal:  Radiol Case Rep        ISSN: 1930-0433


Introduction

Adenylosuccinate lyase deficiency is a rare autosomal recessive disorder of purine metabolism. The disease was described in 1984 in 3 patients with severe psychomotor delay, autistic features, encephalopathy, hypotonia, and elevation of succinylpurines in the urine, cerebrospinal fluid (CSF), and plasma [1]. The accumulation of succinylpurines, succinyladenosine and succinylaminoimidazole carboxamide riboside in biologic fluids is evidence of this disturbance of purine de novo synthesis and purine nucleotide recycling pathways [2], [3]. This enzymatic deficiency can present with a wide array of neurologic symptoms ranging from a fatal neonatal form to a milder clinical presentation with onset during infancy. There have been 3 distinct types of adenylosuccinate lyase deficiency described on a continuum of physical and clinical features. The fatal neonatal type is characterized by encephalopathy, hypotonicity, intractable seizures, and ultimately death within the first week of life [4]. Type I is milder than the fatal neonatal type and is the most common form. It is characterized by microcephaly, severe psychomotor retardation, and seizures. Type II has an onset within the first few years of life and is more slowly progressive with epilepsy, visual impairment, and mild psychomotor retardation as characteristic features. Furthermore, patients with adenylosuccinate lyase deficiency can present with variable dysmorphisms characterized by microcephaly (most common), brachycephaly, flat occiput, prominent metopic suture, divergent strabismus, small nose, smooth philtrum, thin upper lip, and low set ears [2], [3], [4], [5], [6]. Progression of the disorder can be assessed with magnetic resonance imaging (MRI) of the brain. Atrophy of the cerebral cortex, corpus callosum, cerebellar vermis, lack of myelination, delayed myelination, and anomalies of the white matter have been reported [1], [2], [3], [6], [7]. Here, we present a case of an infant with adenylosuccinate lyase deficiency.

Case report

A male child was born at term by an uncomplicated pregnancy. The patient was hypotonic, irritable, and demonstrated poor feeding by breast and bottle in the first week of life. He had a history of in utero hiccups, which persisted as a neonate. At the age of 3 months, he was admitted to the hospital with Respiratory Syncytial Virus (RSV) and seizure-like activity, which prompted an MRI. Videos obtained by family showed that the child had been having seizures since birth. MRI showed myelination confined to the brainstem, central cerebellum, and posterior limbs of the internal capsule (Fig. 1). There was T2 hyperintensity of the white matter (Fig. 2) and superior vermian volume loss (Fig. 3). The corpus callosum was unmyelinated. MRI spectroscopy revealed a low N-acetylaspartate (NAA) peak with no lactate peak (Fig. 4).
Fig. 1

Axial T1-weighted images of the brain acquired at 3.0 T demonstrate myelination limited to the posterior limbs of the bilateral posterior internal capsules (white arrows).

Fig. 2

Axial T2-weighted images of the brain acquired at 3.0 T show increased T2 signal in the periventricular white matter (white arrow). There is overall low parenchymal volume with prominence of the extra-axial spaces (black arrow).

Fig. 3

Sagittal T1-weighted images reveal low parenchymal volume of the superior folia with prominence of the extra-axial spaces (white arrow). The corpus callosum is unmyelinated.

Fig. 4

Magnetic resonance spectroscopy performed at TE = 144 ms with a voxel placed in the right posterior parietal white matter demonstrates a dominant choline peak and a diminished N-acetyl aspartate peak.

Axial T1-weighted images of the brain acquired at 3.0 T demonstrate myelination limited to the posterior limbs of the bilateral posterior internal capsules (white arrows). Axial T2-weighted images of the brain acquired at 3.0 T show increased T2 signal in the periventricular white matter (white arrow). There is overall low parenchymal volume with prominence of the extra-axial spaces (black arrow). Sagittal T1-weighted images reveal low parenchymal volume of the superior folia with prominence of the extra-axial spaces (white arrow). The corpus callosum is unmyelinated. Magnetic resonance spectroscopy performed at TE = 144 ms with a voxel placed in the right posterior parietal white matter demonstrates a dominant choline peak and a diminished N-acetyl aspartate peak. The patient's hospitalization was complicated by seizures requiring prolonged video electroencephalogram (EEG) monitoring and anticonvulsant therapy. CSF analysis yielded an acellular CSF with normal protein and glucose. He was subsequently discharged with a nasogastric tube on phenobarbital therapy at a dose of 10 mg twice a day and levetiracetam at a dose of 75 mg per day. He continued to exhibit excessive hiccupping, episodes of extensor spasms, and multifocal seizures. A follow-up study of the patient's CSF was found to demonstrate abnormally high concentrations of succinyladenosine and succinylaminoimidazole carboxamide riboside. The elevation of these 2 compounds confirmed the diagnosis of adenylosuccinate lyase deficiency.

Discussion

Abnormal myelination in a newborn can be seen with several genetic disorders. Though rare, adenylosuccinate lyase deficiency is a differential consideration in an infant with hypomyelination. Fewer than 100 cases of adenylosuccinate lyase deficiency have been reported with greater prevalence in Belgium and the Netherlands [8]. The low parenchymal volume and prominent cortical sulci may make this disorder distinct from hypomyelination disorders without widened cortical sulci (Figs. 5 and 6).
Fig. 5

Comparison Case. Axial T1-weighted image from a 5-year-old patient with Pelizaeus-Merzbacher disease. Severely delayed myelination is present with limited myelination of the posterior white matter (white arrows). The anterior white matter is not myelinated.

Fig. 6

Comparison Case. Axial T1-weighted image from a 4-month-old female with ring chromosome 18, also a separate hypomyelination disorder. Myelination is confined to the posterior limbs of the bilateral internal capsules (white arrows). The cortical sulci are not widened.

Comparison Case. Axial T1-weighted image from a 5-year-old patient with Pelizaeus-Merzbacher disease. Severely delayed myelination is present with limited myelination of the posterior white matter (white arrows). The anterior white matter is not myelinated. Comparison Case. Axial T1-weighted image from a 4-month-old female with ring chromosome 18, also a separate hypomyelination disorder. Myelination is confined to the posterior limbs of the bilateral internal capsules (white arrows). The cortical sulci are not widened. Hypomyelinating disorders are heterogeneous with multiple known mutations that affect different metabolic processes related to myelin formation. Pelizaeus-Merzbacher disease (Fig. 5), often considered to be the prototypical hypomyelinating disorder, is a genetic neurologic disorder arising from mutations in the proteolipid protein 1 gene [9]. Clinically, the syndrome can present as a spectrum with variable leg weakness, ataxia, hypotonia, and cognitive impairment. MRI findings typically include pronounced frontal lobe predominant hypomyelination [9], [10]. Parenchymal atrophy is seen later in the disease. Patients may also demonstrate signal abnormalities in the basal ganglia and thalami suggestive of iron storage disease, a potential differentiating factor from other pediatric leukodystrophies [9], [10]. Chromosome 18 mutations commonly result in hypomyelination. Ring chromosome 18 (Fig. 6) is a combined deletion involving the long and short arms of chromosome 18. This disorder represents a heterogeneous combination of traits arising from deletions of the short arm (18p) and long arm of the chromosome respectively [11], [12]. The genetic abnormality results in a variable phenotype, which may include developmental delay, seizures, behavioral issues, microcephaly, and obesity among numerous other symptoms [11], [12]. MRI of the brain usually demonstrates hypomyelination in the superior frontal, parietal, and occipital lobes. Myelination is more likely to be normal in the lower frontal and temporal lobes [11]. Ring chromosome 18 patients may also demonstrate ventriculomegaly and occasionally focal lesions such as porencephalic cysts [11]. In common with adenylosuccinate lyase deficiency, cerebellar hypoplasia may manifest with hypomyelinating leukodystrophies caused by mutations on chromosome 18 [13]. Pelizaeus-Merzbacher-like disease is similar to Pelizaeus-Merzbacher disease with hypomyelination of the brainstem [13]. Additional rare hypomyelination diseases with known mutations include oculodentodigital dysplasia, hypomyelination with congenital cataracts, and trichothiodystrophy with photosensitivity [13]. Since metabolic disorders have heterogeneous clinical presentations, MRI may generate important clues to the etiology. In adenylosuccinate lyase deficiency, MRI can show delayed myelination, enlargement of the lateral ventricles, abnormal white matter signal, and volume loss throughout the cerebrum or cerebellum, which is apparent in the first few months of life. Ultimately, metabolic diseases such as adenylosuccinate deficiency require genetic and biochemical testing for definitive diagnosis, but the radiologist may be the first individual to prompt this testing.

Conclusion

Adenylosuccinate lyase deficiency is a hypomyelination disorder that may demonstrate additional parenchymal findings that can distinguish the disease from more common hypomyelinating leukodystrophies. The extreme rarity of adenylosuccinate lyase deficiency in the United States can hinder diagnosis, and the radiologist may suggest genetic testing in the infant presenting with hypomyelination, generalized low parenchymal volume, and superior vermian volume loss.
  12 in total

1.  MR imaging of the brain in five members of a family with Pelizaeus-Merzbacher disease.

Authors:  A M Silverstein; D K Hirsh; J D Trobe; S S Gebarski
Journal:  AJNR Am J Neuroradiol       Date:  1990-05       Impact factor: 3.825

Review 2.  Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders.

Authors:  Grace M Hobson; James Y Garbern
Journal:  Semin Neurol       Date:  2012-03-15       Impact factor: 3.420

3.  Metabolic disorders of purine metabolism affecting the nervous system.

Authors:  H A Jinnah; Richard L Sabina; Georges Van Den Berghe
Journal:  Handb Clin Neurol       Date:  2013

Review 4.  Hypomyelinating disorders: An MRI approach.

Authors:  A James Barkovich; Sean Deon
Journal:  Neurobiol Dis       Date:  2015-10-22       Impact factor: 5.996

5.  Novel proton MR spectroscopy findings in adenylosuccinate lyase deficiency.

Authors:  Maria Zulfiqar; Doris D M Lin; Marinette Van der Graaf; Peter B Barker; Jill A Fahrner; Sandrine Marie; Eva Morava; Lonneke De Boer; Michel A A P Willemsen; Eileen Vining; Alena Horská; Udo Engelke; Ron A Wevers; Gustavo H B Maegawa
Journal:  J Magn Reson Imaging       Date:  2012-10-10       Impact factor: 4.813

6.  Abnormal myelination in ring chromosome 18 syndrome.

Authors:  Ruba Benini; Christine Saint-Martin; Michael I Shevell; Genevieve Bernard
Journal:  J Child Neurol       Date:  2012-01-30       Impact factor: 1.987

7.  Lethal fetal and early neonatal presentation of adenylosuccinate lyase deficiency: observation of 6 patients in 4 families.

Authors:  Katharina Mouchegh; Marie Zikánová; Georg F Hoffmann; Benno Kretzschmar; Thomas Kühn; Eva Mildenberger; Gisela Stoltenburg-Didinger; Jakub Krijt; Lenka Dvoráková; Tomás Honzík; Jiri Zeman; Stanislav Kmoch; Rainer Rossi
Journal:  J Pediatr       Date:  2007-01       Impact factor: 4.406

Review 8.  Magnetic resonance imaging of the brain in adenylosuccinate lyase deficiency: a report of seven cases and a review of the literature.

Authors:  Agnieszka Jurecka; Elzbieta Jurkiewicz; Anna Tylki-Szymanska
Journal:  Eur J Pediatr       Date:  2011-05-31       Impact factor: 3.183

Review 9.  Adenylosuccinate lyase deficiency.

Authors:  Agnieszka Jurecka; Marie Zikanova; Stanislav Kmoch; Anna Tylki-Szymańska
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

10.  A mild form of adenylosuccinate lyase deficiency in absence of typical brain MRI features diagnosed by whole exome sequencing.

Authors:  Marina Macchiaiolo; Sabina Barresi; Francesco Cecconi; Ginevra Zanni; Marcello Niceta; Emanuele Bellacchio; Giacomo Lazzarino; Angela Maria Amorini; Enrico Silvio Bertini; Salvatore Rizza; Benedetta Contardi; Marco Tartaglia; Andrea Bartuli
Journal:  Ital J Pediatr       Date:  2017-08-02       Impact factor: 2.638

View more
  1 in total

1.  Clinical and molecular characterization of patients with adenylosuccinate lyase deficiency.

Authors:  Gerarda Mastrogiorgio; Marina Macchiaiolo; Paola Sabrina Buonuomo; Emanuele Bellacchio; Matteo Bordi; Davide Vecchio; Kari Payne Brown; Natalie Karen Watson; Benedetta Contardi; Francesco Cecconi; Marco Tartaglia; Andrea Bartuli
Journal:  Orphanet J Rare Dis       Date:  2021-03-01       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.